泰格医药
(300347)
| 流通市值：328.40亿 | | | 总市值：499.40亿 |
| 流通股本：5.66亿 | | | 总股本：8.61亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 3,250,444,279.63 | 1,564,143,614.71 | 6,603,120,162.78 | 5,067,615,359.89 |
| 营业收入 | 3,250,444,279.63 | 1,564,143,614.71 | 6,603,120,162.78 | 5,067,615,359.89 |
| 二、营业总成本 | 2,942,263,124.15 | 1,421,418,003 | 5,610,048,004.89 | 4,026,550,519.06 |
| 营业成本 | 2,272,465,808.39 | 1,094,382,708.37 | 4,361,106,945.65 | 3,097,333,423.23 |
| 税金及附加 | 16,314,692.38 | 7,028,108.21 | 28,038,219.79 | 22,385,614.14 |
| 销售费用 | 107,910,230.35 | 48,695,858.78 | 207,607,782.45 | 144,935,323.39 |
| 管理费用 | 355,285,023.64 | 180,487,115.67 | 736,842,477.93 | 558,426,318.44 |
| 研发费用 | 127,004,932.88 | 59,075,766.11 | 238,385,545.75 | 172,098,760.28 |
| 财务费用 | 63,282,436.51 | 31,748,445.86 | 38,067,033.32 | 31,371,079.58 |
| 其中:利息费用 | 54,401,937.67 | - | 141,235,382.04 | - |
| 其中:利息收入 | 8,422,574.46 | - | 90,219,275.91 | - |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -89,643,957.92 | -22,391,786.77 | -501,688,166.32 | -34,411,947.15 |
| 加:投资收益 | 233,000,832.99 | 25,309,680.34 | 166,642,230.65 | 109,158,171.38 |
| 资产处置收益 | 625,757.46 | 577,115.15 | 3,563,278.83 | 2,674,931.25 |
| 资产减值损失(新) | -4,294,719.2 | -3,523,796.53 | 1,254,555.47 | -10,657,299.51 |
| 信用减值损失(新) | -25,015,431.51 | -11,100,193.38 | -35,275,311.28 | -44,439,217.18 |
| 其他收益 | 21,404,223.43 | 12,907,751.88 | 36,850,266.27 | 21,606,421.27 |
| 四、营业利润 | 444,257,860.73 | 144,504,382.4 | 664,419,011.51 | 1,084,995,900.89 |
| 加:营业外收入 | 497,380.27 | 159,536.46 | 5,090,122.07 | 5,337,204.28 |
| 减:营业外支出 | 2,065,905.52 | 1,038,576.02 | 5,047,625.28 | 3,268,133.42 |
| 五、利润总额 | 442,689,335.48 | 143,625,342.84 | 664,461,508.3 | 1,087,064,971.75 |
| 减:所得税费用 | 79,861,031.64 | 33,644,494.98 | 216,630,221.33 | 183,929,494.79 |
| 六、净利润 | 362,828,303.84 | 109,980,847.86 | 447,831,286.97 | 903,135,476.96 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 362,828,303.84 | 109,980,847.86 | 447,831,286.97 | 903,135,476.96 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 383,337,133.84 | 165,468,741.43 | 405,143,491.82 | 813,428,915.46 |
| 少数股东损益 | -20,508,830 | -55,487,893.57 | 42,687,795.15 | 89,706,561.5 |
| 扣除非经常损益后的净利润 | 210,752,394.83 | 102,328,863.87 | 854,895,425.22 | 892,098,006.45 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.45 | 0.19 | 0.47 | 0.94 |
| (二)稀释每股收益 | 0.45 | 0.19 | 0.47 | 0.94 |
| 八、其他综合收益 | 48,983,183.82 | 5,329,777.35 | -30,367,462.62 | -50,709,884.36 |
| 归属于母公司股东的其他综合收益 | 36,845,539.93 | 5,939,283.19 | -4,438,571.01 | -26,157,226.69 |
| 九、综合收益总额 | 411,811,487.66 | 115,310,625.21 | 417,463,824.35 | 852,425,592.6 |
| 归属于母公司股东的综合收益总额 | 420,182,673.77 | 171,408,024.62 | 400,704,920.81 | 787,271,688.77 |
| 归属于少数股东的综合收益总额 | -8,371,186.11 | -56,097,399.41 | 16,758,903.54 | 65,153,903.83 |
| 公告日期 | 2025-08-29 | 2025-04-29 | 2025-03-28 | 2024-10-30 |
| 审计意见(境内) | | | 标准无保留意见 | |